A Therapeutic Platform Through Inhibition of Fe–S Cluster Biogenesis and Ribonucleotide Reductase for Infectious Diseases and Cancer

The problem:

Iron is indispensable to life. As the central co-factor in enzymes spanning electron transport, DNA synthesis, and sulfur mobilization, iron occupies a position of unparalleled metabolic importance. Bacteria, parasites, fungi, viruses, and cancer cells have all evolved mechanisms not only to compete aggressively for iron in iron-limited environments, but also to up-regulate iron-dependent enzymatic systems in proportion to their proliferative demands. This shared dependency creates a therapeutic window: by targeting iron-dependent systems that are disproportionately essential in pathogens and malignant cells relative to healthy human tissue, it becomes possible to achieve selective toxicity at concentrations that spare normal host cells.

The hypothesis

I propose that simultaneously inhibiting two of the most “iron-hungry” processes in any cell; iron–sulfur (Fe–S) cluster biogenesis and ribonucleotide reductase (RNR) may arrest growth more effectively than inhibiting either alone, in cells that rely heavily on both systems. Healthy, quiescent cells, which carry redundant Fe–S machinery and low baseline RNR activity, may tolerate the same pressure. The platform has two targets. Each can also be developed on its own, but the central hypothesis coupled with a rationally designed molecular entity concerns their combination.

Why it matters:

No existing therapeutic agent, whether clinically advanced (Triapine, hydroxyurea), preclinical (iron-pool sequestrants), or early-discovery (SufS inhibitors such as compound '882 and EAC), achieves direct dual inhibition of both targets through rational molecular design. Because the two mechanisms converge on growth arrest through independent routes, Fe–S proteome inactivation on one side, dNTP pool collapse on the other, a single point mutation is unlikely to confer resistance to both simultaneously, creating a mechanistic burden that is inherently resistant to single-step escape. If valid; a single platform could address infections and cancers that currently need separate drug classes, not to mention cross-species infections.

Initial rationale

Both pathways are iron-dependent and both are required wherever cells proliferate under stress. If the differential-demand logic holds, selectivity could arise from biology rather than from binding affinity alone.

What this series will explore

The following posts/incoming updates will review the existing evidence and the precise gap this project addresses, define a quantitative validation plan, document the implementation of that plan as a cross-species therapeutics platform, report the first findings, show how the approach was refined in response and close the cycle with a current conclusion and the concrete next phase.

Next step

Reviewing what is already known about Fe–S cluster biogenesis and RNR as drug targets, and identify the specific gap that this project addresses.